Summary

Performance

Immunogen

Application

Background

Appears to modulate the interaction of APOE with beta-migrating VLDL and inhibit binding of beta-VLDL to the LDL receptor-related protein. Binds free fatty acids and reduces their intracellular esterification. Inhibitor of lipoprotein binding to the low density lipoprotein (LDL) receptor, LDL receptor-related protein, and very low density lipoprotein (VLDL) receptor. Associates with high density lipoproteins (HDL) and the triacylglycerol-rich lipoproteins in the plasma and makes up about 10% of the protein of the VLDL and 2% of that of HDL. Appears to interfere directly with fatty acid uptake and is also the major plasma inhibitor of cholesteryl ester transfer protein (CETP). Binds free fatty acids and reduces their intracellular esterification. Modulates the interaction of APOE with beta-migrating VLDL and inhibits binding of beta-VLDL to the LDL receptor-related protein.

Research Area

Cardiovascular; Lipids / Lipoproteins; Lipoproteins/Apolipoproteins; Lipoproteins; Fatty Acids; Binding proteins; Signal Transduction; Metabolism; Lipid metabolism; Atherosclerosis; Lipoprotein metabolism; Metabolism Pathways and Processes; Metabolic signaling pathways; Lipid and lipoprotein metabolism; Heart disease; Pathways and Processes; Redox metabolism; Fatty acid oxidation